Initiate the Phase 2 monotherapy study of HLP004 for generalized anxiety disorder
Deadline not yet reached (155 days left)
- Announced
- 21 Oct 2026
- Due
- 31 Mar 2027
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“HLP004 Program progressing with Phase 2 monotherapy study for the potential treatment of generalized anxiety disorder ("GAD") expected to initiate in Q1 2027”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2027.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 monotherapy study of HLP004 for generalized anxiety disorder
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Helus Pharma Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-HELP-019887 · Corrections policy